Michael Severino Biography and Net Worth

Vice Chairman of AbbVie

Dr. Michael Severino is Vice Chairman and President, responsible for research and development and the corporate strategy office. He previously served as Executive Vice President, Research & Development and Chief Scientific Officer of AbbVie.

Prior to joining AbbVie in 2014, Dr. Severino was Senior Vice President, Global Development and Chief Medical Officer at Amgen, Inc. During his time at Amgen, he served in roles of increasing responsibility across a broad range of therapeutic areas including oncology, inflammation, neuroscience, cardiovascular and metabolic disorders.

Dr. Severino serves on the Board of Directors for Avantor and the Board of Trustees for the Field Museum. At AbbVie, he is the executive chair of the Black Business Network Employee Resource Group.

He earned a bachelor’s degree in biochemistry from the University of Maryland, College Park and a doctorate in medicine from The Johns Hopkins University in Baltimore, Maryland, U.S.A. Dr. Severino completed his residency and fellowship training at the Massachusetts General Hospital and Harvard Medical School in Boston, Massachusetts, U.S.A.

What is Michael Severino's net worth?: The estimated net worth of Michael Severino is at least $25.86 million as of May 23rd, 2022. Dr. Severino owns 152,103 shares of AbbVie stock worth more than $25,859,031 as of April 21st. This net worth evaluation does not reflect any other assets that Dr. Severino may own. Learn More about Michael Severino's net worth.
How do I contact Michael Severino?: The corporate mailing address for Dr. Severino and other AbbVie executives is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. AbbVie can also be reached via phone at (847) 932-7900. Learn More on Michael Severino's contact information.
Has Michael Severino been buying or selling shares of AbbVie?: Michael Severino has not been actively trading shares of AbbVie during the last quarter. Most recently, Michael Severino sold 79,801 shares of the business's stock in a transaction on Monday, May 23rd. The shares were sold at an average price of $150.90, for a transaction totalling $12,041,970.90. Following the completion of the sale, the insider now directly owns 152,103 shares of the company's stock, valued at $22,952,342.70. Learn More on Michael Severino's trading history.
Who are AbbVie's active insiders?: AbbVie's insider roster includes Carlos Alban (Vice Chairman), Roxanne Austin (Director), Kevin Buckbee (SVP), Nicholas Donoghoe (SVP), Brian Durkin (VP), Richard Gonzalez (CEO), Henry Gosebruch (EVP), Robert Michael (Vice Chairman), Scott Reents (Sr. VP & CFO ), Scott Reents (CFO), Timothy Richmond (EVP), Azita Saleki-Gerhardt (EVP), Laura Schumacher (Vice Chairman), Michael Severino (Vice Chairman), Perry Siatis (EVP), Elaine Sorg (SVP), Jeffrey Stewart (EVP), and Carrie Strom (SVP). Learn More on AbbVie's active insiders.
Are insiders buying or selling shares of AbbVie?: During the last year, insiders at the sold shares 7 times. They sold a total of 464,616 shares worth more than $85,637,938.10. The most recent insider tranaction occured on March, 31st when EVP Jeffrey Ryan Stewart sold 58,832 shares worth more than $12,359,426.56. Insiders at AbbVie own 0.3% of the company. Learn More about insider trades at AbbVie.
Information on this page was last updated on 3/31/2025.

Michael Severino Insider Trading History at AbbVie

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/23/2022	Sell	79,801	$150.90	$12,041,970.90	152,103
5/16/2022	Sell	100,000	$154.45	$15,445,000.00	152,103
5/9/2022	Sell	100,000	$150.28	$15,028,000.00	152,103
5/6/2022	Sell	100,000	$150.81	$15,081,000.00	152,103
8/17/2018	Sell	50,000	$97.52	$4,876,000.00	111,481
11/10/2017	Sell	25,633	$94.69	$2,427,188.77	114,922

Michael Severino Buying and Selling Activity at AbbVie

AbbVie Company Overview

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Today's Range

Now: $170.01

$168.54

$174.17

50 Day Range

MA: $198.01

$170.01

$216.62

2 Week Range

Now: $170.01

$153.58

$218.66

Volume

7,360,966 shs

Average Volume

6,010,855 shs

Market Capitalization

$300.74 billion

P/E Ratio

70.84

Dividend Yield

3.66%

Beta

0.55